What is the proper protocol for transitioning a patient from a heparin drip to enoxaparin (Lovenox) injections?

Transitioning from Heparin Drip to Lovenox Injections

Stop the heparin infusion and start enoxaparin 1 mg/kg subcutaneously every 12 hours without any overlap or bridging period required. 1, 2

Transition Protocol

Standard Dosing

• Discontinue the heparin drip when you're ready to transition
• Start enoxaparin 1 mg/kg subcutaneously every 12 hours immediately
• No need to wait for aPTT to normalize
• No overlap period is necessary

Dose Adjustments for Special Populations

Renal Impairment (CrCl <30 mL/min):

• Reduce to 1 mg/kg subcutaneously once daily 1, 2

Elderly Patients (≥75 years) receiving fibrinolytic therapy:

• Use 0.75 mg/kg subcutaneously every 12 hours without initial IV bolus 2, 3

Obese Patients (BMI ≥40 kg/m²):

• Consider 0.8 mg/kg subcutaneously every 12 hours 4

Critical Warnings

Do NOT Switch Back and Forth

Patients initially treated with enoxaparin should not be switched to UFH and vice versa because of increased risk of bleeding (Class III recommendation). 3 Once you commit to enoxaparin, stay with it unless there's a compelling contraindication.

Timing Considerations for PCI

If the patient requires PCI after starting enoxaparin 1, 2:

• If last dose was <8 hours ago: Give no additional enoxaparin
• If last dose was 8-12 hours ago: Give IV bolus of 0.3 mg/kg enoxaparin
• If only one dose given or >12 hours: Give IV bolus of 0.3 mg/kg enoxaparin

Monitoring

No routine aPTT monitoring is needed with enoxaparin—this is one of its major advantages over UFH. The predictable pharmacokinetics eliminate the need for frequent lab draws that heparin requires.

Anti-Xa monitoring is generally not required for standard dosing but may be considered in:

• Severe renal impairment
• Extreme body weights
• Pregnancy
• Suspected treatment failure

Target anti-Xa level for therapeutic dosing: 0.5-1.0 units/mL (drawn 4 hours after dose) 5

Duration of Therapy

Continue enoxaparin for the duration of the index hospitalization, up to 8 days, or until revascularization 6, 7. If transitioning to warfarin, overlap for minimum 5 days and until INR is therapeutic (2.0-3.0) for 2 consecutive days 8.

Common Pitfalls to Avoid

1. Don't taper or bridge: There's no need for a gradual transition or overlap period when switching from heparin to enoxaparin
2. Don't underdose in renal failure: Remember to adjust for CrCl <30 mL/min to avoid accumulation
3. Don't forget about timing before procedures: The 8-hour rule for PCI is critical to avoid both thrombosis and bleeding
4. Don't switch anticoagulants unnecessarily: Switching between UFH and enoxaparin increases bleeding risk significantly

Practical Administration

Enoxaparin should be administered by deep subcutaneous injection in the anterolateral or posterolateral abdominal wall. Inject slowly over 30 seconds and wait 10 seconds before withdrawing the needle to minimize ecchymosis 9. Do not expel the air bubble before injection.